Introduction
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Our results support findings that LEV monotherapy is effective and well tolerated in children with BECTS. Prospective, large, long-term double-blind studies are needed to confirm these findings. # 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. sleep organization; peculiar focal or multifocal centrotemporal spikes (CTS), increasing in frequency during sleep. 3, 4 This type of epilepsy generally tends to follow a benign course and the treatment is often not required. However, treatment decision requires clinical judgment and observations over time. In fact, treatment is started in subjects with frequent seizures and/or seizures that recur during wakefulness, or when the ictal events are disruptive to the patient or family. 5, 6 Once assumed the treatment option, it may be suitable to choose the best tolerated antiepileptic drug (AED), possibly at the minimal effective dosage. Valproic acid and Carbamazepine are the most frequently prescribed AED in this type of epilepsy. 1, 5 More recently, based on the particularly favourable pharmacokinetic profile and the good tolerability, Levetiracetam (LEV) has been successfully considered as monotherapy option; the pharmacokinetic profile of LEV makes this AED a good option for the treatment of pediatric patients. 7 LEV is a novel AED which has been approved as adjunctive treatment for adults with partial onset seizures. Its mechanisms of action appear different from other AEDs. 8 LEV binds to a specific membrane-binding site in the brain. 9 It neither affects glutamate or gamma aminobutyric acidmediated synaptic transmission, 10, 11 nor does it modulate voltage dependent sodium or T-type calcium currents. 12 LEV is well tolerated and its effectiveness was established in multicenter, wellcontrolled pivotal trials. [13] [14] [15] The safety profile is consistent with that observed in many epilepsy trials. [16] [17] [18] Moreover, LEV has proven efficacy in the treatment of partial seizures with or without secondary generalization and refractory epilepsies;
19-21 but preliminary observations are favourable for a broader use.
Therefore, LEV is widely used but the experience in BECTS is limited, in fact, only Bello-Espinoza. 22 have reported three cases of young children with typical BECTS treated with LEV.
The objective of this study was to generate information on LEV monotherapy in a group of children and adolescents with BECTS.
Patients and methods
Twenty-one subjects (15 male; 6 female) with BECTS were enrolled in this prospective study from five centers of Italy. All patients have been diagnosed with this type of epilepsy, according to the International League Against Epilepsy (ILAE) 3 . The age of seizures onset ranged from 5.0 to 12.1 years, with a peak of frequency at mean AE S.D. 7.7 AE 4.4 years.
All patients showed typical rolandic seizures. The typical seizures were hemifacial, characterized by clonic manifestations involving the hemiface, sometimes preceded by unilateral paresthesia involving toungue, lips, gums and cheek; the jerks were often associated with a lateral tonic deviation of the mouth involving lips and toungue, and result drooling due to sialorrhoea. The seizures lasted from less than a minute to 3 min, and spreaded to the homolateral arm and rarely to the leg. No permanent deficits were observed in all cases.
Exclusion criteria were: neurological disorders or intellectual impairment, history or presence of pseudoseizures, history of recurrent psychotic or major effective disorder, the use of CNS-influencing medication, unless patients had been stabilized on such medication for >1 months before the study, metabolic disorders, active infection or neoplasm, any clinically relevant progressive or serious illness expected to interfere with the patient completing the trial, previous treatment with LEV discontinued due to adverse events.
In all cases, computed tomography or magnetic resonance imaging before the trial confirmed the absence of neoplasia or progressive cerebral or neurodegenerative diseases.
In all patients, electroencephalograms (EEG) were recorded during wakefulness with hyperventilation and photic stimulation and during drowsiness and sleep (stages 1-4); all patients show a normal, well-organized and symmetrical background activity. We recorded only interictal EEGs: in all patients we found typical CTS, clearly localized in the central regions; the main spikes component was diphasic with a maximum surface, negative, rounded peak followed by a smaller positive peak; this was followed by a negative or negative-positive slow wave. A relatively minute positive spike often preceded this spike-slow wave complex. The spikes significantly increased in frequency during drowsiness and through all sleep stages.
LEV was administered as a first drug (number of patients = 9) or converted after previous treatment with other AEDs (number of patients = 12). Therefore, the 21 patients were subdivided into two groups: ''newly diagnosed'' (AED naïve) group and ''converted'' group. In this second group of patients, different AEDs were tried before introducing TPM treatment: Valproate (4 patients), Carbamazepine (6 patients), Oxcarbazepine (1 patient), Lamotrigine (1 patient). All patients received these AEDs monotherapy. In these 12 patients preexisting AED treatment was gradually tapered during titration phase of LEV.
All patients began LEV 250 mg each evening and dosing was escalated gradually; after titration, LEV was administered, the range of prescribed LEV dosages ranged from 1000 to 2500 mg/daily. All patients were carefully followed at 6 and 12 months after the beginning of LEV therapy. At each visit, the investigator assessed the number and type of seizures, adverse events, with their severity, relationship to LEV treatment, and outcome. Each treatment-emergent physical and neurological abnormality was recorded as adverse event, as was any condition worsening or requiring initiation of medication. Height and weight were monitored throughout the trial.
Physical and neurologic examinations, laboratory assessment and electrocardiography were performed, and vital signs were recorded; during the baseline and the treatment periods and at study completion, detailed records of adverse events were documented.
During the follow-up, in all patients were performed the following laboratorial examinations: complete peripheral blood counts, urinary analysis and measurement of blood creatinine, alanine and aspartate aminotransferase levels, erythrocyte and leukocyte count, amylase, transaminase, BUN.
Compared with baseline seizures frequency and severity, the response to LEV treatment was classified as: seizures free (100% seizures control); responders (>50% reduction) or marginal effect (<50% reduction) in monthly seizures frequency.
The evaluation of the patients started after the end of LEV titration. The efficacy of LEV therapy was calculated by counting mean seizures frequency/ months; in particular, baseline period was 6 months before LEV treatment; visit 6 months: mean seizures frequency for the period ''after the end of tritation'' 6 months; visit 12 months: mean seizures frequency for the period 6-12 months.
Data of the patients are reported as mean AE S.D.
Results
No patients were lost during follow-up. All patients remained on LEV therapy during the 12 months.
Efficacy Table 1 illustrates changes in seizures frequency at 6 months and 12 months of follow-up. During the first 6 months of the study 8 (30.1%) patients of the naïve group and 9 (42.8%) patients of second group became seizure free. At the end of follow-up, 9 (42.8%) ''newly diagnosed patients'' and 8 (30.1%) ''converted patients'' showed complete cessation of seizures. One patient of the second group has been controlled for 6 months, but than relapsed and at the end, was classified as ''responder''.
Tolerability
Adverse reactions occurred in 2 (9.5%) patients; in these two patients drowsiness and irritability was reported during the initial phase (2 weeks) of treatment and than disappeared. No other important adverse effects were observed during the therapy. No findings of major clinical significance were noted regarding the effects of study medication on laboratory test results, vital signs, electrocardiographic recordings, physical and neurologic examinations, and phychiatric and mental status.
Discussion
Considering the spontaneous benign course of BECTS a continuous treatment should be considered only in subjects with frequent seizures. Moreover, patients with frequent seizures and secondarily generalized tonic-clonic seizures may need medication.
1,4 LEV has proven efficacy in this type of epilepsy as has been recently reported by Bello-Espinoza. 22 Also our study has evaluated the efficacy and the safety of LEV in the treatment of BECTS. This study suggests that LEV monotherapy can be effective and very well tolerated in BECTS at the onset of disease as well as far who failed other AEDs prior to LEV treatment. In addition, this study shows a high retention rate of LEV with all patients able to continue on LEV for 12 months. We treated two different types of patients: naive patients and converted patients and the response was significantly better in naive patients. Recently, it has been underlined that this epilepsy is a challenge in terminology and classification, 23 because BECTS is a heterogeneous condition which includes a large spectrum of clinical features; 2, 24, 25 the atypical features could influence the response to treatment. 1, 26 Although efficacy as measured by seizure frequency is the principal outcome evaluated in studies, of great importance to the patient is the change in quality of life made possible by a new treatment. With regard to safety, LEV has been reported to be a well-tolerated drug. Adverse reactions, mainly represented by headache, infection, somnolence and anorexia, have been reported, with the incidence varying from 10 to 19%. 27, 28 Acute psychosis has also been reported. [29] [30] [31] [32] In our experience, LEV has shown to be well tolerated, in fact, only two patients reported transient somnolence and irritability. Somnolence, dizziness, and headache were three most frequent events also in the large study performed by Tsai and Yen. 18 We confirm that these side effects are transient, in fact, previous studies showed that somnolence occurs predominantly during the initial phase of treatment with LEV. 16, 18 Generally, adverse events of LEV were typically of a non-serious nature, mild-to-moderate in intensity, and only slightly more frequent than in placebo-treated patients. 33 This study provides further support for the LEV safety: no discontinuation due to adverse events was reported in our study, confirming that LEV is a drug with a safe profile.
The small number of patients studied, as well as the nature of this study and the short-term followup, along with lack of randomization may not allow us to make firm conclusions. However, our preliminary data suggest that LEV may be an acceptable choice as monotherapy for BECTS.
